Fortress Biotech, Inc. Annual report pursuant to Section 13 and 15(d)

Licenses Acquired (Journey and Other - Narrative) (Details)

Licenses Acquired (Journey and Other - Narrative) (Details) $ / shares in Units, $ in Thousands			1 Months Ended			12 Months Ended		18 Months Ended
	Nov. 16, 2021 D $ / shares shares	Jun. 29, 2021 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	May 31, 2021 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2022 USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and development - licenses acquired						$ 677	$ 15,625
Licensing Agreements [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and development - licenses acquired						677	15,625
Journey \| Dr. Reddy's Laboratories, Ltd [Member] \| Contingent Payment Warrant [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Warrants, fair value			$ 3,800			3,800		$ 3,800
Journey \| Licensing Agreements [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and development - licenses acquired						0	13,819
Journey \| Licensing Agreements [Member] \| Dr. Reddy's Laboratories, Ltd [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Upfront fees payment		$ 10,000
Payments for research and development expenses								$ 13,000
Research and development - licenses acquired							10,000
Shares issued, price per share \| $ / shares	$ 9.1721
Shares issued \| shares	545,131
Number of trading days for calculating volume weighted average price per share \| D	15
Product cease period		6 months
Journey \| Licensing Agreements [Member] \| Dr. Reddy's Laboratories, Ltd [Member] \| Achievement of Certain Clinical Development, Regulatory and First Commercial Sale milestones [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payments of milestones		$ 158,000
Journey \| Licensing Agreements [Member] \| Dr. Reddy's Laboratories, Ltd [Member] \| Period after product regulatory or first commercial sale
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Agreement termination term upon failure to initiate product development		24 months
Journey \| Licensing Agreements [Member] \| Dr. Reddy's Laboratories, Ltd [Member] \| Period after product regulatory
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Agreement termination term upon failure to initiate product development		72 months
Journey \| Licensing Agreements [Member] \| Minimum \| Dr. Reddy's Laboratories, Ltd [Member] \| Payable on Net Sales of the DFD-29 Product [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Sales royalties (as a percent)		0.10%
Journey \| Licensing Agreements [Member] \| Maximum \| Dr. Reddy's Laboratories, Ltd [Member] \| Payable on Net Sales of the DFD-29 Product [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Sales royalties (as a percent)		0.15%
Urica \| Licensing Agreements [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and development - licenses acquired						$ 300	$ 0
Urica \| Licensing Agreements [Member] \| Fuji Yakuhin Co. Ltd [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payments of milestones				$ 3,000
One-time amendment payment			$ 300
Urica \| Licensing Agreements [Member] \| Minimum \| Fuji Yakuhin Co. Ltd [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Sales royalties (as a percent)					7.00%
Urica \| Licensing Agreements [Member] \| Maximum \| Fuji Yakuhin Co. Ltd [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payments of milestones					$ 88,000
Sales royalties (as a percent)					10.00%